Israel Englander Coherus Bio Sciences, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 1,049,603 shares of CHRS stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,049,603

Previous 797,511 31.61%

Holding current value

$1.12 Million

Previous $829,000 74.67%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.67 - $1.71 $168,901 - $431,077	252,092 Added 31.61%	1,049,603 $1.45 Million
Q3 2024 Nov 14, 2024	BUY	$0.99 - $1.8 $179,668 - $326,669	181,483 Added 29.46%	797,511 $829,000
Q2 2024 Aug 14, 2024	SELL	$1.58 - $2.51 $1.01 Million - $1.61 Million	-641,335 Reduced 51.01%	616,028 $1.07 Million
Q1 2024 May 15, 2024	SELL	$2.02 - $3.14 $3.2 Million - $4.98 Million	-1,584,956 Reduced 55.76%	1,257,363 $3.01 Million
Q4 2023 Feb 14, 2024	BUY	$1.59 - $3.85 $3.16 Million - $7.66 Million	1,989,851 Added 233.42%	2,842,319 $9.46 Million
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $2.4 Million - $5.26 Million	633,994 Added 290.19%	852,468 $3.64 Million
Q1 2023 May 15, 2023	SELL	$5.89 - $10.52 $1.91 Million - $3.41 Million	-324,147 Reduced 59.74%	218,474 $1.49 Million
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $144,901 - $256,442	25,466 Added 4.92%	542,621 $4.3 Million
Q3 2022 Nov 14, 2022	BUY	$7.17 - $13.87 $916,684 - $1.77 Million	127,850 Added 32.84%	517,155 $4.97 Million
Q2 2022 Aug 15, 2022	BUY	$5.86 - $13.23 $1.1 Million - $2.48 Million	187,245 Added 92.67%	389,305 $2.82 Million
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $1.4 Million - $2.11 Million	-128,381 Reduced 38.85%	202,060 $2.61 Million
Q4 2021 Feb 14, 2022	SELL	$15.81 - $18.99 $2.43 Million - $2.92 Million	-153,584 Reduced 31.73%	330,441 $5.27 Million
Q3 2021 Nov 15, 2021	BUY	$12.68 - $17.79 $2.99 Million - $4.2 Million	235,903 Added 95.08%	484,025 $7.78 Million
Q2 2021 Aug 16, 2021	SELL	$12.95 - $15.41 $2.01 Million - $2.39 Million	-155,288 Reduced 38.49%	248,122 $3.43 Million
Q1 2021 May 17, 2021	BUY	$14.42 - $21.39 $5.82 Million - $8.63 Million	403,410 New	403,410 $5.89 Million
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $5.1 Million - $6.77 Million	-353,446 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$11.67 - $22.53 $3.4 Million - $6.56 Million	-290,997 Reduced 45.15%	353,446 $5.73 Million
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $9.31 Million - $12.2 Million	570,157 Added 767.52%	644,443 $11.6 Million
Q3 2019 Nov 14, 2019	SELL	$16.3 - $23.37 $1.69 Million - $2.42 Million	-103,441 Reduced 58.2%	74,286 $1.51 Million
Q2 2019 Aug 15, 2019	SELL	$13.1 - $22.1 $3.85 Million - $6.49 Million	-293,728 Reduced 62.3%	177,727 $3.93 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $3.6 Million - $6.08 Million	-274,907 Reduced 36.83%	471,455 $25.3 Million
Q1 2019 May 14, 2019	BUY	$8.38 - $15.5 $6.25 Million - $11.6 Million	746,362 New	746,362 $10.2 Million
Q4 2018 Feb 14, 2019	SELL	$8.65 - $16.28 $4.46 Million - $8.4 Million	-516,059 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$14.45 - $20.25 $179,960 - $252,193	12,454 Added 2.47%	516,059 $8.52 Million
Q2 2018 Aug 14, 2018	BUY	$10.25 - $17.45 $3.53 Million - $6.01 Million	344,240 Added 216.01%	503,605 $7.05 Million
Q1 2018 May 15, 2018	SELL	$9.1 - $13.7 $4.88 Million - $7.34 Million	-535,921 Reduced 77.08%	159,365 $1.76 Million
Q4 2017 Feb 14, 2018	BUY	$8.35 - $14.4 $5.2 Million - $8.97 Million	623,248 Added 865.17%	695,286 $6.12 Million
Q3 2017 Nov 14, 2017	BUY	$11.1 - $14.5 $799,621 - $1.04 Million	72,038	72,038 $962,000

Others Institutions Holding CHRS

# of Institutions

130

Shares Held

67.8M

Call Options Held

1.68M

Put Options Held

91.8K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $83.2M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account